The landscape of AML therapy is quickly evolving, with new agents improving the response in molecular subgroups, such as FLT3-ITD or FLT3-TKD treated with midostaurin30 or IDH1/2-mutated AML treated with specific inhibitors31,32. Here, IDH1 is linked to acute myeloid leukemia.